Company
Since 1909, Grifols has worked to improve the health and well-being of people around the world.
Innovation
Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.
Sustainability
Grifols' longstanding commitment to people and the planet entails helping society on all fronts.
Investors
Stock Information
Financials
Communications with CNMV and SEC
Corporate Governance
Careers
People are at the heart of our business. We are committed to continued investment in training and development.
Media
Latest news about the company and contact information for journalists and communication professionals.
Partners
At Grifols, we believe in long-term, mutually trusting relationships with our partners.
Connect with us
Showing 474 search results
Grifols announces topline phase 3 data on long-term Albutein® (albumin [human] U.S.P.) therapy for decompensated cirrhosis with ascites
Grifols ranked number one biotech company in Dow Jones Sustainability Indices
Grifols concludes balance sheet improvement process with private placement of Senior Secured Notes and Revolving Credit Facility extension
Grifols’ Board of Directors Announces Termination of Acquisition Discussions with Brookfield
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus
Grifols Delivers Strong Third-Quarter Performance Led by Biopharma 12.1% Growth
Grifols awarded Gold Medal by EcoVadis for Sustainability Excellence
Grifols receives FDA approval to treat surgical bleeding in pediatric patients with its fibrin sealant solution
Grifols receives SBTi approval for its near-term science-based emission reduction targets
Grifols partners with BARDA for proof-of-concept testing of ocular immunoglobulin as treatment for sulfur mustard-induced eye injury
Grifols achieves its highest-ever score in the 2024 S&P Global Sustainability Assessment
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat